{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:38:57Z","timestamp":1782848337171,"version":"3.54.5"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T00:00:00Z","timestamp":1649808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,25]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The aim of this study was to systematically review and compare the quantitative effect of clinical interventions designed to improve adherence to urate-lowering therapy. MEDLINE, Embase, CINAHL, Scopus and Web of Science were searched for interventional studies reporting quantitative adherence to urate-lowering therapy information as an endpoint. Intervention details, quantitative adherence information, clinical outcome and cost-effectiveness data were extracted. Risk of bias was assessed. From 4721 records, 11 studies (3 randomised and 8 observational) met the inclusion criteria. Pharmacist- and nurse-led interventions were described, involving a mixture of patient education, telephone or mobile texting reminders, and medication blister packing. Quantitative adherence information was obtained using methods such as patient self-reporting and pharmacy-dispensing data. Most studies had a moderate-to-high risk of bias. Two of the three randomised studies reported improvement in adherence between the intervention and control groups, including a 13% increase in the mean proportion of days covered &amp;gt;0.8 [341\/681 participants (50%) versus 289\/782 participants (37%)] and an 88% increase in achieving a high Medicine Taking Behaviour questionnaire score [37\/42 participants (88.1%) versus 0\/40 participants (0%)]. Four of the eight observational studies reported improved adherence from baseline (ranging from 33% to 91% based on the longitudinal change in adherence metrics reported). A comparison of the different types of interventions was not feasible due to the heterogeneity between study designs and adherence metrics used. These findings support the need for more interventional studies to be conducted to aid adherence management.<\/jats:p>","DOI":"10.1093\/ijpp\/riac025","type":"journal-article","created":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T04:16:01Z","timestamp":1646799361000},"page":"215-225","source":"Crossref","is-referenced-by-count":16,"title":["Clinical interventions to improve adherence to urate-lowering therapy in patients with gout: a systematic review"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6813-6022","authenticated-orcid":false,"given":"Klarissa A","family":"Sinnappah","sequence":"first","affiliation":[{"name":"School of Pharmacy, University of Otago , Dunedin , New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie L","family":"Stocker","sequence":"additional","affiliation":[{"name":"Sydney Pharmacy School, University of Sydney , Sydney , Australia"},{"name":"Clinical Pharmacology & Toxicology, St Vincent\u2019s Hospital , Sydney , Australia"},{"name":"St Vincent\u2019s Clinical School, Faculty of Medicine, University of New South Wales , Sydney , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian Sheng","family":"Chan","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology & Toxicology, St Vincent\u2019s Hospital , Sydney , Australia"},{"name":"St Vincent\u2019s Clinical School, Faculty of Medicine, University of New South Wales , Sydney , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8247-7459","authenticated-orcid":false,"given":"Dyfrig A","family":"Hughes","sequence":"additional","affiliation":[{"name":"Bangor University , Bangor , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F B","family":"Wright","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Otago , Dunedin , New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,4,13]]},"reference":[{"key":"2022062503011656700_CIT0001","volume-title":"Gout. Oxford Rheumatology Library.","author":"Dalbeth","year":"2016","edition":"1"},{"key":"2022062503011656700_CIT0002","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.rdc.2014.01.006","article-title":"Structural joint damage in gout","volume":"40","author":"Chhana","year":"2014","journal-title":"Rheum Dis Clin North Am"},{"key":"2022062503011656700_CIT0003","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/acr.24180","article-title":"2020 American College of Rheumatology guideline for the management of gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Care & Research"},{"key":"2022062503011656700_CIT0004","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1136\/annrheumdis-2019-215315","article-title":"2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout","volume":"79","author":"Richette","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022062503011656700_CIT0005","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1592\/phco.28.4.437","article-title":"Comparison of drug adherence rates among patients with seven different medical conditions","volume":"28","author":"Briesacher","year":"2008","journal-title":"Pharmacotherapy"},{"key":"2022062503011656700_CIT0006","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/acr.22336","article-title":"Medication adherence in gout: a systematic review","volume":"66","author":"De Vera","year":"2014","journal-title":"Arthritis Care & Research"},{"key":"2022062503011656700_CIT0007","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1093\/rheumatology\/key237","article-title":"Can we predict inadequate response to allopurinol dose escalation? Analysis of a randomised controlled trial","volume":"57","author":"Stamp","year":"2018","journal-title":"Rheumatology (Oxford, England)"},{"key":"2022062503011656700_CIT0008","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2022062503011656700_CIT0009","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/MLR.0b013e31829b1d2a","article-title":"Standardising terminology and definitions of medication adherence and persistence in research employing electronic databases","volume":"51","author":"Raebel","year":"2013","journal-title":"Med Care"},{"key":"2022062503011656700_CIT0010","first-page":"14898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2022062503011656700_CIT0011","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"2022062503011656700_CIT0012","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"2022062503011656700_CIT0013","first-page":"529","article-title":"Long-term persistence and adherence on urate-lowering treatment can be maintained in primary care-5-year follow-up of a proof-of-concept study","volume":"56","author":"Abhishek","year":"2017","journal-title":"Rheumatology"},{"key":"2022062503011656700_CIT0014","first-page":"155","article-title":"Mobile phone text messages for improving allopurinol adherence: a randomised controlled trial of text message reminders","volume":"77","author":"Bunphong","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2022062503011656700_CIT0015","first-page":"u210130. w4918","article-title":"Gout in primary care: can we improve patient outcomes?","author":"Callear","year":"2017"},{"key":"2022062503011656700_CIT0016","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.semarthrit.2016.10.006","article-title":"Pilot study of a multidisciplinary gout patient education and monitoring program","volume":"46","author":"Fields","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2022062503011656700_CIT0017","first-page":"575","article-title":"Nurse-led care is preferred over GP-led care of gout and improves gout outcomes: results of Nottingham Gout Treatment Trial follow-up study","volume":"59","author":"Fuller","year":"2020","journal-title":"Rheumatology (UK)."},{"key":"2022062503011656700_CIT0018","first-page":"935","article-title":"eHealth supported collaborative care for gout involving rheumatology, pharmacy, and dietetics: mid-term outcomes","volume":"44","author":"Howren","year":"2017","journal-title":"J Rheumatol"},{"key":"2022062503011656700_CIT0019","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1071\/HC18082","article-title":"Facilitating equitable prevention and management of gout for Maori in Northland, New Zealand, through a collaborative primary care approach","volume":"11","author":"Lawrence","year":"2019","journal-title":"Journal of primary health care"},{"key":"2022062503011656700_CIT0020","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.amjmed.2018.11.011","article-title":"Adherence and outcomes with urate-lowering therapy: a site-randomized trial","volume":"132","author":"Mikuls","year":"2019","journal-title":"Am J Med"},{"key":"2022062503011656700_CIT0021","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s40744-020-00249-w","article-title":"High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: who\u2019s to Blame?","volume":"7","author":"Perez-Ruiz","year":"2020","journal-title":"Rheumatology and Therapy"},{"key":"2022062503011656700_CIT0022","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/1756-185X.13855","article-title":"A nurse-led, rheumatologist-assisted telemedicine intervention for dose escalation of urate-lowering therapy in gout","volume":"23","author":"Phang","year":"2020","journal-title":"International Journal of Rheumatic Diseases"},{"key":"2022062503011656700_CIT0023","first-page":"1143","article-title":"The patient education for gout patients ameliorate the patients\u2019 satisfaction and serum uric acid level","volume":"69","author":"Yoo","year":"2017","journal-title":"Arthritis and Rheumatology Conference"},{"key":"2022062503011656700_CIT0024","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1136\/annrheumdis-2012-201676","article-title":"Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study","volume":"72","author":"Rees","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2022062503011656700_CIT0025","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(18)32158-5","article-title":"Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial","volume":"392","author":"Doherty","year":"2018","journal-title":"Lancet"},{"key":"2022062503011656700_CIT0026","volume-title":"Medication Event Monitoring Systems (MEMS\u00ae) [Internet]","author":"AARDEX Group","year":"2019"},{"key":"2022062503011656700_CIT0027","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/1759720X18807117","article-title":"Effectiveness of healthcare educational and behavioral interventions to improve gout outcomes: a systematic review and meta-analysis","volume":"10","author":"Ramsubeik","year":"2018","journal-title":"Therapeutic Advances in Musculoskeletal Disease"},{"issue":"3","key":"2022062503011656700_CIT0028","doi-asserted-by":"crossref","DOI":"10.3399\/bjgpopen20X101051","article-title":"Interventions to improve uptake of uratelowering therapy in patients with gout: a systematic review","volume":"4","author":"Gill","year":"2020","journal-title":"BJGP Open"},{"key":"2022062503011656700_CIT0029","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/cpt.1454","article-title":"Integration of pharmacometrics and pharmacoeconomics to quantify the value of improved forgiveness to nonadherence: a case study of novel xanthine oxidase inhibitors for gout","volume":"106","author":"Hill-McManus","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"2022062503011656700_CIT0030","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1111\/jan.14025","article-title":"A systematic review and meta-analysis on the effectiveness of education on medication adherence for patients with hypertension, hyperlipidaemia and diabetes","volume":"75","author":"Tan","year":"2019","journal-title":"J Adv Nurs"},{"key":"2022062503011656700_CIT0031","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2022062503011656700_CIT0032","doi-asserted-by":"crossref","first-page":"e0172","DOI":"10.1136\/bmjopen-2017-017281","article-title":"Effectiveness of an electronic patient-centred self-management tool for gout sufferers: a cluster randomised controlled trial protocol","volume":"7","author":"Day","year":"2017","journal-title":"BMJ open"},{"key":"2022062503011656700_CIT0033","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","article-title":"A new taxonomy for describing and defining adherence to medications","volume":"73","author":"Vrijens","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"2022062503011656700_CIT0034","first-page":"268","article-title":"scoping review of studies comparing the medication event monitoring system (MEMS) with alternative methods for measuring medication adherence","author":"El Alili","year":"2016"},{"key":"2022062503011656700_CIT0035","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jval.2018.06.002","article-title":"Impact of non-adherence and flare resolution on the cost-effectiveness of treatments for gout: application of a linked pharmacometric\/pharmacoeconomic model","volume":"21","author":"Hill-McManus","year":"2018","journal-title":"Value Health"}],"container-title":["International Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijpp\/article-pdf\/30\/3\/215\/44249341\/riac025.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijpp\/article-pdf\/30\/3\/215\/44249341\/riac025.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T23:21:31Z","timestamp":1726788091000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijpp\/article\/30\/3\/215\/6568062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,13]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,4,13]]},"published-print":{"date-parts":[[2022,6,25]]}},"URL":"https:\/\/doi.org\/10.1093\/ijpp\/riac025","relation":{},"ISSN":["0961-7671","2042-7174"],"issn-type":[{"value":"0961-7671","type":"print"},{"value":"2042-7174","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2022,4,13]]}}}